Literature DB >> 23357107

Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making.

Etienne Cavalier, Pierre Delanaye, Olivier Moranne.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23357107     DOI： 10.1053/j.ajkd.2012.12.013

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  13 in total

Review 1.  Biomarkers Predicting Bone Turnover in the Setting of CKD.

Authors:  Pieter Evenepoel; Etienne Cavalier; Patrick C D'Haese
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

2.  Efficiency of delivery observed treatment in hemodialysis patients: the example of the native vitamin D therapy.

Authors:  Pierre Delanaye; Etienne Cavalier; Coraline Fafin; Bernard E Dubois; Jean-Marie Krzesinski; Olivier Moranne
Journal:  J Nephrol       Date:  2015-04-10       Impact factor: 3.902

3.  European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates for serum biointact parathyroid hormone based on weekly samplings from 91 healthy participants.

Authors:  Michela Bottani; Giuseppe Banfi; Elena Guerra; Massimo Locatelli; Aasne K Aarsand; Abdurrahman Coşkun; Jorge Díaz-Garzón; Pilar Fernandez-Calle; Sverre Sandberg; Ferruccio Ceriotti; Elisabet González-Lao; Margarita Simon; Anna Carobene
Journal:  Ann Transl Med       Date:  2020-07

Review 4.  The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations.

Authors:  Annemieke C Heijboer; Etienne Cavalier
Journal:  Calcif Tissue Int       Date:  2022-06-04       Impact factor: 4.333

Review 5.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

6.  Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.

Authors:  A Neuprez; S Coste; E Rompen; J M Crielaard; J Y Reginster
Journal:  Osteoporos Int       Date:  2013-07-09       Impact factor: 4.507

Review 7.  Fibroblast growth factor 23: are we ready to use it in clinical practice?

Authors:  Annet Bouma-de Krijger; Marc G Vervloet
Journal:  J Nephrol       Date:  2020-03-04       Impact factor: 3.902

Review 8.  FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.

Authors:  Anna Kurpas; Karolina Supeł; Karolina Idzikowska; Marzenna Zielińska
Journal:  Dis Markers       Date:  2021-05-17       Impact factor: 3.434

9.  Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients.

Authors:  Guillaume Jean; Jean-Claude Souberbielle; Eric Zaoui; Christie Lorriaux; Jean-Marc Hurot; Brice Mayor; Patrik Deleaval; Manolie Mehdi; Charles Chazot
Journal:  BMC Nephrol       Date:  2016-10-18       Impact factor: 2.388

10.  Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients.

Authors:  Pierre Delanaye; Xavier Warling; Martial Moonen; Nicole Smelten; François Jouret; Jean-Marie Krzesinski; Nicolas Maillard; Hans Pottel; Etienne Cavalier
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.